Get the Stockscreener App
7.40
19.16%
1.19
Gt Biopharma Inc stock is traded at $7.40, with a volume of 57,243.
It is up +19.16% in the last 24 hours and down -17.78% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$6.21
Open:
$6.5
24h Volume:
57,243
Relative Volume:
1.56
Market Cap:
$13.35M
Revenue:
$63,000
Net Income/Loss:
$-47.73M
P/E Ratio:
-0.5139
EPS:
-14.3996
Net Cash Flow:
$-13.18M
1W Performance:
+24.16%
1M Performance:
-17.78%
6M Performance:
-23.71%
1Y Performance:
-59.65%
1-Day Range:
$6.50
$7.40
1-Week Range:
$5.8269
$7.50
52-Week Range:
$4.9101
$28.75
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GTBP
Gt Biopharma Inc
|
7.40 | 13.35M | 63,000 | -47.73M | -13.18M | -14.40 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Form S-1 GT Biopharma Inc For: 9 October By Investing.com - Investing.com Canada
Gt Biopharma Selling Stockholders To Offer Up To 13,502,835 Shares Of Common Stock - TradingView
TRex Bio Files for Nasdaq IPO - Yahoo! Finance Canada
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
GT Biopharma regains Nasdaq compliance: what it means for GT Biopharma stock - AD HOC NEWS
GT Biopharma sells USD 7.75 million: what it means for GT Biopharma stock - AD HOC NEWS
With $31.2M left to sell, GT Biopharma (GTBP) has made its first equity sale. - stocktitan.net
BioHarvest Sciences launches buyback of up to 5% of shares - Yahoo! Finance Canada
GT Biopharma Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
GT Biopharma Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
GT Biopharma regains Nasdaq $1.00 minimum bid compliance after 10-day stretch - TradingView
GT Biopharma Expands Series M Preferred Financing Agreement - The Globe and Mail
GT Biopharma Upsizes Preferred Stock Offering to US$7.75 Million With New Investor - minichart.com.sg
GT Biopharma Increases Series M Preferred Stock Private Placement with New Investor - Kalkine Media
GT Biopharma Expands Private Placement to $8.61M Stated Value, Adds Greenshoe Up to $34.7M - TradingView
GT Biopharma (Nasdaq:GTBP)Stock Analysis - Simply Wall Street
New investor hits 9.99% ceiling in GT Biopharma (GTBP) - Stock Titan
GT Biopharma announces $7.45 million private placement of preferred stock and warrants - Investing.com Nigeria
Form 8K GT Biopharma Inc For: 15 September By Investing.com - Investing.com Nigeria
Form 8K GT Biopharma Inc For: 15 September By Investing.com - Investing.com UK
GT Biopharma announces $7.45 million private placement of preferred stock and warrants - Investing.com UK
Form 8K GT Biopharma Inc For: 15 September By Investing.com - Investing.com South Africa
Why Has GT Biopharma (GTBP) Become a Talking Point? - Kalkine Media
GT Biopharma, Inc. announced that it expects to receive $30 million in funding - marketscreener.com
Why Has GT Biopharma (GTBP) Become a Talking Point? - kalkinemedia.com
GTBP: Phase I TriKE trials show early promise, with key data expected soon and broad expansion potential - TradingView
Price to sales ratio of GT Biopharma Inc – MUN:OXI - tradingview.com
EBITDA per share of GT Biopharma Inc – MUN:OXI - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
GTBP Price Today: GT Biopharma Inc. Stock Price, Quote & Chart | MEXC - MEXC
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 - marketscreener.com
A live briefing will cover a platform designed to help immune cells kill cancer - Stock Titan
EBITDA per share of GT Biopharma Inc – FWB:OXI - TradingView
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsSuperTrend - siam.in
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsFactor Rotation - vinanet.vn
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure - TipRanks
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsInitial Balance - dars.gov.et
GTBP stock holds steady as GT Biopharma advances TriKE cancer pipeline - ad-hoc-news.de
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes - Eastern Progress
Stock Quotes, Business News and Data from Stock Markets | MSN Money - MSN
GTBP Q1 2026 Earnings: EPS Misses Estimates as Stock Drops 3.72%Dividend Cut Risk - vinanet.vn
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan - TipRanks
GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan
GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million - scanx.trade
Gt Biopharma Reports Second Quarter 2026 Financial Results - TradingView
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):